JP2022502405A - 多形化合物およびその使用 - Google Patents

多形化合物およびその使用 Download PDF

Info

Publication number
JP2022502405A
JP2022502405A JP2021516916A JP2021516916A JP2022502405A JP 2022502405 A JP2022502405 A JP 2022502405A JP 2021516916 A JP2021516916 A JP 2021516916A JP 2021516916 A JP2021516916 A JP 2021516916A JP 2022502405 A JP2022502405 A JP 2022502405A
Authority
JP
Japan
Prior art keywords
compound
disease
patient
stroke
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021516916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502405A5 (https=
JPWO2020069068A5 (https=
Inventor
ラッセル バーチ ポー，
デイビッド ティー． ヨナイティス，
リサ ミシェル グローブ，
Original Assignee
アストロサイト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アストロサイト ファーマシューティカルズ， インコーポレイテッド filed Critical アストロサイト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2022502405A publication Critical patent/JP2022502405A/ja
Publication of JP2022502405A5 publication Critical patent/JP2022502405A5/ja
Publication of JPWO2020069068A5 publication Critical patent/JPWO2020069068A5/ja
Priority to JP2024104074A priority Critical patent/JP2024114885A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2021516916A 2018-09-26 2019-09-26 多形化合物およびその使用 Pending JP2022502405A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024104074A JP2024114885A (ja) 2018-09-26 2024-06-27 多形化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736979P 2018-09-26 2018-09-26
US62/736,979 2018-09-26
PCT/US2019/053076 WO2020069068A1 (en) 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024104074A Division JP2024114885A (ja) 2018-09-26 2024-06-27 多形化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2022502405A true JP2022502405A (ja) 2022-01-11
JP2022502405A5 JP2022502405A5 (https=) 2022-10-04
JPWO2020069068A5 JPWO2020069068A5 (https=) 2022-10-04

Family

ID=69885558

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516916A Pending JP2022502405A (ja) 2018-09-26 2019-09-26 多形化合物およびその使用
JP2024104074A Pending JP2024114885A (ja) 2018-09-26 2024-06-27 多形化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024104074A Pending JP2024114885A (ja) 2018-09-26 2024-06-27 多形化合物およびその使用

Country Status (12)

Country Link
US (2) US10765693B2 (https=)
EP (1) EP3856741A4 (https=)
JP (2) JP2022502405A (https=)
KR (1) KR20210093864A (https=)
CN (1) CN112930349A (https=)
AU (1) AU2019346585B2 (https=)
BR (1) BR112021005290A2 (https=)
CA (1) CA3113250A1 (https=)
EA (1) EA202190576A1 (https=)
IL (1) IL281718A (https=)
MX (1) MX2021003515A (https=)
WO (1) WO2020069068A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
IL276358B2 (en) 2018-02-09 2024-11-01 Astrocyte Pharmaceuticals Inc Compounds and methods for treating addiction and related disorders
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
MX2023014655A (es) 2021-07-12 2024-01-12 Acadia Pharm Inc Formas cristalinas de trofinetida.
WO2023091791A1 (en) * 2021-11-22 2023-05-25 Astrocyte Pharmaceuticals, Inc. Methods of treating neurological and cardiovascular conditions
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
WO2006091905A1 (en) * 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2017185061A1 (en) * 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US7087589B2 (en) * 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
JP4012070B2 (ja) 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US7557092B2 (en) 2002-11-21 2009-07-07 University Of Utah Research Foundation Purinergic modulation of smell
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
WO2007139775A2 (en) 2006-05-23 2007-12-06 University Of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US7867983B2 (en) 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
US20100256086A1 (en) 2007-11-23 2010-10-07 Bar-Ilan Univetrsity Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2429565A4 (en) 2009-04-15 2012-11-14 Univ California NEURONIC OR NERVE PEPTIDES AND APTAMERS
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
ES2654363T3 (es) 2010-02-22 2018-02-13 University Of Connecticut Derivados de AMP para tratar enfermedades cardíacas
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
EA034135B9 (ru) 2013-03-13 2020-04-10 Тафтс Юниверсити Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
WO2015080940A1 (en) 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
EP3253388A4 (en) 2015-02-04 2018-11-21 Baker Heart and Diabetes Institute A method of treatment and compounds for use therein
IL276358B2 (en) * 2018-02-09 2024-11-01 Astrocyte Pharmaceuticals Inc Compounds and methods for treating addiction and related disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
WO2006091905A1 (en) * 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2017185061A1 (en) * 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
""新医薬品の規格及び試験方法の設定について"", 医薬審発第568号, JPN6010021254, 1 May 2001 (2001-05-01), ISSN: 0005269918 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), pages 907 - 69, ISSN: 0005269920 *
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005269917 *
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0005269921 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005269919 *

Also Published As

Publication number Publication date
IL281718A (en) 2021-05-31
KR20210093864A (ko) 2021-07-28
JP2024114885A (ja) 2024-08-23
US10765693B2 (en) 2020-09-08
WO2020069068A1 (en) 2020-04-02
AU2019346585B2 (en) 2025-02-27
WO2020069068A9 (en) 2020-05-14
EP3856741A1 (en) 2021-08-04
CN112930349A (zh) 2021-06-08
BR112021005290A2 (pt) 2021-06-22
NZ774215A (en) 2025-03-28
MX2021003515A (es) 2021-05-27
US20200093848A1 (en) 2020-03-26
EA202190576A1 (ru) 2021-09-03
US20210077518A1 (en) 2021-03-18
US11324769B2 (en) 2022-05-10
AU2019346585A1 (en) 2021-04-29
EP3856741A4 (en) 2022-06-22
CA3113250A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP2022502405A (ja) 多形化合物およびその使用
US20230049327A1 (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EA032526B1 (ru) Применение ингибитора кинуренин-3-монооксигеназы для лечения заболеваний и состояний, опосредованных активностью кинуренин-3-монооксигеназы
US20250188017A1 (en) Polymorphic compounds and uses thereof
JP6526652B2 (ja) グルコシルセラミドシンターゼ阻害剤としてのｎ−（１−ヒドロキシ−３−（ピロリジニル）プロパン−２−イル）ピロリジン−３−カルボキサミド誘導体
CN101411716B (zh) 虎杖苷用于制备抗痴呆产品的用途
TW200810752A (en) Modulators of muscarinic receptors
EP3828193A1 (en) Crystal form of lanosterol prodrug compound and application thereof
CN109071524A (zh) 作为eaat2活化剂的哒嗪衍生物
CA3232914A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
TW200914442A (en) Gamma secretase modulators
KR20240158230A (ko) 중수소-풍부 피페리디닐-메틸-퓨린 아민 및 관련 화합물 및 질환 및 병태 치료에 있어서 이것들의 용도
EP1148881A1 (fr) UTILISATION DE DERIVES DE PYRIDAZINO [4,5-(b)]-INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
EP3860981A1 (en) Niraparib salts
EA046380B1 (ru) Полиморфные формы соединения a и их фармацевтические композиции
CN110267661A (zh) 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐
ES3035604T3 (en) Forms and compositions of inhibitors of plasma kallikrein
US20230279021A1 (en) Polymorphs of a gabaa alpha5 agonist and methods of using in the treatment of cognitive impairment
TWI885324B (zh) 環己烯酮化合物之結晶形
HK40117665A (zh) 环己酮化合物的晶型
CN117143074A (zh) 3-苄氧基-6-吡啶基哒嗪类化合物及其制备方法和用途
CN106588775A (zh) 一种吲唑衍生物及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227